Which has the lower trailing P/E, PODD or PTGX?

PODD has the lower trailing P/E: PODD trades at 25.30 and PTGX at 132.50. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, PODD or PTGX?

Over the past five years, PTGX grew revenue faster — PODD at a 25.13% CAGR versus PTGX at 59.63%.

Is PODD or PTGX more profitable?

PTGX runs the higher net margin — PODD at 12.29% versus PTGX at 29.40%.

How have PODD and PTGX total returns compared?

Over the past 10 years, PODD delivered 13.11% and PTGX delivered 20.54% annualized total return. Past performance doesn't predict future results.

Insulet Corp. (PODD) vs Protagonist Therapeutics, Inc. (PTGX)

A side-by-side comparison of Insulet Corp. and Protagonist Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

PODD

Insulet Corp.

$9.37B

$135.33HealthcareDelayed quote: Oct 6, 2026, 1:15 PM EDT

PTGX

Protagonist Therapeutics, Inc.

$8.81B

$136.97HealthcareDelayed quote: Oct 6, 2026, 1:15 PM EDT

Total return — PODD vs PTGX

growth of $100 · dividends reinvested · last 10y

PODD +242.0% (+13.1%/yr)PTGX +574.2% (+21.0%/yr)PTGX compounded faster over this window

PODD PTGX

PODD vs PTGX: by the numbers

•PODD is the larger company ($9.37B vs $8.81B market cap).
•PODD trades at the lower trailing earnings multiple (25.30 vs 132.50 P/E), one valuation lens rather than an overall verdict.
•PTGX converts more revenue to profit (29.40% vs 12.29% net margin).
•PTGX grew revenue faster over the past five years (59.63% vs 25.13% CAGR).

Metrics side by side

Valuation

Metric	PODD	PTGX
P/E ratio	25.30	132.50
Forward P/E	20.81	N/A
PEG ratio	0.24	N/A
P/S ratio	3.07	31.24
P/B ratio	6.59	10.47
EV / EBITDA	15.75	140.23
FCF yield	3.18%	1.48%

Profitability

Metric	PODD	PTGX
Gross margin	71.08%	99.86%
Operating margin	16.89%	-343.63%
Net margin	12.29%	29.40%
ROE	26.39%	9.85%
ROIC	16.04%	6.74%

Growth (annualized)

Metric	PODD	PTGX
Revenue CAGR (5Y)	25.13%	59.63%
EPS CAGR (5Y)	99.91%	N/A
Total return CAGR (5Y)	-13.93%	50.88%

Frequently asked

Which has the lower trailing P/E, PODD or PTGX?: PODD has the lower trailing P/E: PODD trades at 25.30 and PTGX at 132.50. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, PODD or PTGX?: Over the past five years, PTGX grew revenue faster — PODD at a 25.13% CAGR versus PTGX at 59.63%.
Is PODD or PTGX more profitable?: PTGX runs the higher net margin — PODD at 12.29% versus PTGX at 29.40%.
How have PODD and PTGX total returns compared?: Over the past 10 years, PODD delivered 13.11% and PTGX delivered 20.54% annualized total return. Past performance doesn't predict future results.

Go deeper

Full PODD analysis Full PTGX analysis Interactive comparison tool

Dig into the metrics

Insulet P/E ratio Protagonist Therapeutics P/E ratio Insulet ROE Protagonist Therapeutics ROE Insulet operating margin Protagonist Therapeutics operating margin Insulet revenue growth Protagonist Therapeutics revenue growth Insulet free cash flow Protagonist Therapeutics free cash flow

Insulet & Protagonist Therapeutics appear in these rankings

Fastest Revenue Growth Stocks Highest ROE Stocks Highest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.